Our previous studies have shown that relatively early-stage Alzheimer's disease (AD) patients have already endured a significant deterioration in the structure of their semantic knowledge. Given that AD is a progressive disease, the patients' semantic network should manifest a further deterioration by the later stages of their disease. To evaluate the nature and degree of this deterioration, the present study will use multidimensional scaling techniques (MDS) to compare the semantic networks of mildly (Mid-AD), moderately (Mod-AD) and severely (Sev-AD) demented AD patients. It is anticipated that the semantic networks of Mid-AD, Mod-AD and Sev-AD will be different in terms of the primary dimension of organization, the clustering of concepts and in the variance or heterogeneity of performances within each group. Understanding the semantic networks of AD patients in different stages of the disease is both theoretically and clinically significant. Given that AD results in severe pathological changes in the cortex, examining the semantic networks of AD patients will help in understanding the different neuronal pathways by which different components of semantic information are stored and distributed. On a clinical level, a thorough knowledge of the progressive changes in AD patient's semantic space could have importance for the early detection and accurate staging of the disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005131-13
Application #
5204438
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
1996
Total Cost
Indirect Cost
Young, Jessica E; Fong, Lauren K; Frankowski, Harald et al. (2018) Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer's Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein. Stem Cell Reports 10:1046-1058
Golde, Todd E; DeKosky, Steven T; Galasko, Douglas (2018) Alzheimer's disease: The right drug, the right time. Science 362:1250-1251
Reas, Emilie T; Hagler Jr, Donald J; White, Nathan S et al. (2018) Microstructural brain changes track cognitive decline in mild cognitive impairment. Neuroimage Clin 20:883-891
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Graves, Lisa V; Holden, Heather M; Van Etten, Emily J et al. (2018) New Yes/No Recognition Memory Analysis on the California Verbal Learning Test-3: Clinical Utility in Alzheimer's and Huntington's Disease. J Int Neuropsychol Soc 24:833-841
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Fong, Lauren K; Yang, Max M; Dos Santos Chaves, Rodrigo et al. (2018) Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid-? clearance in human astrocytes. J Biol Chem 293:11341-11357
Edmonds, Emily C; Ard, M Colin; Edland, Steven D et al. (2018) Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimers Dement (N Y) 4:11-18
Spencer, Brian; Brüschweiler, Sven; Sealey-Cardona, Marco et al. (2018) Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders. Acta Neuropathol 136:69-87

Showing the most recent 10 out of 914 publications